External validation of a prediction model for bleeding events in anticoagulated cancer patients with venous thromboembolism (PredictAI)
Viñuela-Benéitez, María Carmen (Universidad Complutense de Madrid)
Iglesias Pérez, Claudia (Hospital Universitario Central de Asturias)
Ortega Morán, Laura (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
García Escobar, Ignacio (Hospital Universitario de Toledo)
Cacho Lavín, Diego (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Porta i Balanyà, Rut (Hospital Universitari de Girona Doctor Josep Trueta)
García Adrián, Silvia (Hospital Universitario de Móstoles (Madrid))
Carmona Campos, Marta (Complejo Hospitalario Universitario de Santiago de Compostela)
Benítez López, Gretel (Complejo Hospitalario Materno Insular de Gran Canaria)
Santiago Crespo, José Antonio (ospital Virgen de La Luz (Cuenca))
Lobo de Mena, Miriam (Hospital General Universitario de Valencia)
Pérez Altozano, Javier (Hospital General Universitario de Elche)
Gallardo Díaz, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Tejerina Peces, Julia (Hospital Universitario Clínico San Carlos (Madrid))
Ochoa Rivas, Pilar (Hospital Central de la Defensa Gómez Ulla)
Ortiz Morales, María José (Hospital General Universitario Reina Sofía (Múrcia, Múrcia))
Castellón Rubio, Victoria Eugenia (Hospital Universitario Torrecárdenas (Almeria, Andalusia))
Díez Pedroche, Carmen (Hospital Universitario 12 de Octubre (Madrid))
Rosales Sueiro, María (Portuguese Institute of Oncology of Porto)
Gonçalves, Felipe (Portuguese Institute of Oncology of Lisbon Francisco Gentil)
Sánchez Cánovas, Manuel (Hospital General Universitario Morales Meseguer (Múrcia))
Ruiz, Miguel Ángel (Universidad Autónoma de Madrid)
Muñoz-Langa, José (Hospital Arnau de Vilanova (València))
Pérez Segura, Pedro (Hospital Universitario Clínico San Carlos (Madrid))
de Castro, Eva Martínez (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia))
Jimenez-Fonseca, Paula (Hospital Universitario Central de Asturias)
Muñoz Martin, Andrés (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Universitat Autònoma de Barcelona

Data:	2025
Resum:	The objective of this study was to validate the PredictAI models for predicting major bleeding (MB) in patients with active cancer and venous thromboembolism (VTE) with anticoagulant (ACO) therapy, within 6 months after primary VTE, using an independent cohort of patients from the TESEO database. This study conducted an external validation of the PredictAI models using the international, prospective TESEO registry from July 2018 until October 2021. Data from 40 Spanish and Portuguese hospitals recruiting consecutive cases of cancer-associated thrombosis under anticoagulant treatment and without missing values regarding the model outcome or predictors were used. Patients with baseline MB or unknown MB status during follow-up were excluded for the validation analysis. Logistic regression (LR), decision tree (DT), and random forest (RF) approaches were used to validate the models. Included patients from the TESEO cohort (2179 patients) had similar key demographics and clinical characteristics to the PredictAI cohort (21,227 patients). During the 6-month follow-up period, 10. 9% (n = 2314) and 5. 9% (n = 129) of patients experienced at least one MB event in the PredictAI and TESEO cohorts, respectively. Hemoglobin, metastasis, age, platelets, leukocytes, and serum creatinine were described as predictors for MB in PredictAI; the external validation results in TESEO showed statistical significance by LR and RF approaches, with ROC-AUC values of 0. 59 and 0. 56, respectively (both p < 0. 05). PredictAI models for predicting MB in anticoagulant-treated cancer patients within the first 6 months following VTE diagnosis have been externally validated. These models may be considered as a tool to guide objective decisions regarding the indication or extension of anticoagulant therapy in this population. The online version contains supplementary material available at 10. 1007/s12094-025-03890-5.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Cancer ; Venous thromboembolism ; Bleeding ; Anticoagulation ; Natural language processing
Publicat a:	Clinical & translational oncology, Vol. 27 (april 2025) , p. 4031-4039, ISSN 1699-3055

DOI: 10.1007/s12094-025-03890-5
PMID: 40287561

9 p, 834.5 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d’Investigació i Innovació Parc Taulí (I3PT)
Articles > Articles de recerca
Articles > Articles publicats